Results 161 to 170 of about 1,177,924 (224)

Replenishing co‐downregulated miR‐100‐5p and miR‐125b‐5p in malignant germ cell tumors causes growth inhibition through cell cycle disruption

open access: yesMolecular Oncology, Volume 19, Issue 4, Page 1203-1228, April 2025.
MiR‐99a‐5p/miR‐100‐5p (functionally identical) and miR‐125b‐5p microRNAs are downregulated in malignant germ cell tumors (GCTs). Combination replenishment of these microRNAs using mimics resulted in growth inhibition in representative cell lines, with consequent downregulation of target genes involved in cell cycle (confirmed by flow cytometry) and ...
Marta Ferraresso   +12 more
wiley   +1 more source

Gut microbiota diversity is prognostic and associated with benefit from chemo‐immunotherapy in metastatic triple‐negative breast cancer

open access: yesMolecular Oncology, Volume 19, Issue 4, Page 1229-1243, April 2025.
We assessed the associations between the gut microbiota and outcome in metastatic triple‐negative breast cancer patients treated with chemotherapy alone or chemotherapy in combination with immunotherapy. Our data indicate that high gut microbiota alpha diversity was associated with improved clinical outcome and with benefit from immunotherapy.
Andreas Ullern   +8 more
wiley   +1 more source

Vertical inhibition of p110α/AKT and N‐cadherin enhances treatment efficacy in PIK3CA‐aberrated ovarian cancer cells

open access: yesMolecular Oncology, Volume 19, Issue 4, Page 1132-1154, April 2025.
PIK3CA amplification and PIK3CA mutation enhance ovarian tumorigenicity through an activation of AKT, which phosphorylates YAP at Ser127. This Ser127 phosphorylation leads to the retention of YAP in the cytoplasm and triggers RAC1 activity, promoting cell migration. Additionally, AKT activation increases expression of N‐cadherin, which further enhances
Shibo Zhang   +6 more
wiley   +1 more source

Integrative systems‐level analysis reveals a contextual crosstalk between hypoxia and global metabolism in human breast tumors

open access: yesMolecular Oncology, EarlyView.
Breast tumor samples scored for metabolic deregulation (M1 to M3) were given a hypoxia score (HS). The highest HS occurred in patients with strongest metabolic deregulation (M3), supporting tumor aggressiveness. HS correlated with the highest number of metabolic pathways in M1. This suggests hypoxia to be an early event in metabolic deregulation.
Raefa Abou Khouzam   +2 more
wiley   +1 more source

Crosstalk between gut microbiota and tumor: tumors could cause gut dysbiosis and metabolic imbalance

open access: yesMolecular Oncology, EarlyView.
In this research, we analyzed the relationship between gut microbiota and tumor. We discovered that both subcutaneous and metastatic tumors would alter the composition and metabolic function of gut microbiota. Meanwhile, fecal microbiota transplantation also indicated the anti‐tumor role of the gut microbiota, revealing the crosstalk between tumor and ...
Siyuan Zhang   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy